

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk

Application No.: 09/585,817

Filed: June 1, 2000

For: PREVENTION AND TREATMENT  
OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon

Art Unit: 1647

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
C.F.R. §§ 1.97 and 1.98

RECEIVED  
AUG 22 2002

TECH CENTER RECEIVED  
AUG 19 PM 2:04  
SER 1600/2900  
#10

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The references cited on attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

The Assignee of the instant application is a licensee of U.S. Patent No. 5,688,651, which is directed in part to subject matter related to the instant application. U.S. Patent No. 5,688,651 is now undergoing examination reissue as Application No. 09/441,140. U.S. Application No. 09/441,140 is cited in the PTO/SB/08A form attached hereto. U.S. Patent No. 5,688,651 was cited in the IDS submitted April 30, 2001.

In addition to the commonly owned copending applications directed to related subject matter cited in the IDS submitted April 30, 2000, Applicant wishes to bring the following applications to the Examiner's attention:

09/979,952 filed 11/26/01 (U.S. National Stage of PCT/US00/15239 filed

06/01/00;

RECEIVED

AUG 22 2002

PATENT

TECH CENTER 1600/2900

RECEIVED 1600/2900  
TECH CENTER 1600/2900  
02 AUG 19 PM 2:02

09/979,701 filed 11/26/01 (U.S. National Stage of PCT/US00/14810 filed  
05/26/00; and,  
09/980,568 filed 03/12/02 (U.S. National Stage of PCT/US00/15302 filed  
06/01/00).


In addition to the commonly owned abandoned applications directed to related  
subject matter cited in the IDS submitted April 30, 2001, Applicant wishes to bring the following  
application to the Examiner's attention:

60/137,047 filed 06/01/99.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a  
search has been conducted or that this statement encompasses all the possible relevant  
information, and no inference should be made that the information and references cited are, or  
are considered to be material to patentability because they are in this statement. No inference  
should be made that the information and references cited are prior art merely because they are in  
this statement.

Applicant believes that no fee is required for submission of this statement, since it  
is being submitted prior to the first Office Action. However, if a fee is required, the  
Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-  
1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted  
Deposit Account.

Respectfully submitted,

  
Rosemarie L. Celli  
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
RLC  
PA 3243009 v1